Focused On-demand Library for Large ribosomal subunit protein mL40

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NQ50

UPID:

RM40_HUMAN

Alternative names:

39S ribosomal protein L40, mitochondrial; Nuclear localization signal-containing protein deleted in velocardiofacial syndrome; Up-regulated in metastasis

Alternative UPACC:

Q9NQ50; B3KVZ7; O95134

Background:

The Large ribosomal subunit protein mL40, also known as 39S ribosomal protein L40, mitochondrial, plays a crucial role in protein synthesis within mitochondria. It is alternatively named as Nuclear localization signal-containing protein deleted in velocardiofacial syndrome and Up-regulated in metastasis, indicating its diverse functions and potential involvement in various cellular processes.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein mL40 could open doors to potential therapeutic strategies. Its involvement in protein synthesis and potential link to cellular processes pivotal in disease states highlights its importance in drug discovery.